Clinical trials: Non-Communicable Chronic Diseases
Chronic Hepatitis C, Hepatitis, Viral, Human
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
The purpose of this study is to assess the safety and efficacy of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT00230854
- Testing
- EMZ702
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- OPKO Health, Inc.
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
Chronic Hepatitis c
Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
- Trial name
- NCT05138523
- Testing
- Sofosdac®
- Where
- 4 sites in Algeria
- Volunteers
- 99 people
- Sponsor
- Beker Laboratories
Hepatitis C, Chronic
Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)
To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.
- Trial name
- POMOSCH (NCT01098097)
- Testing
- Peginterferon alpha, Ribavirin
- Volunteers
- 963 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.
- Trial name
- MALACHITE 1 (NCT01854697)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir
- Volunteers
- 311 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
This prospective, multi-center, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) in participants with previously untreated chronic hepatitis C, genotype 2, 3, 1…
- Trial name
- PEGHOPE (NCT01416610)
- Where
- 10 sites in Austria
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
- Trial name
- ENDURANCE-2 (NCT02640482)
- Testing
- ABT-493/ABT-530
- Volunteers
- 304 people
- Sponsor
- AbbVie
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
- Trial name
- NCT02570191
- Testing
- Peginterferon alfa-2a
- Where
- 8 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
This open--label, multicenter, national observational study will investigate the effectiveness of standard of care treatment with peginterferon alfa-2a in participants with chronic hepatitis B (CHB).
- Trial name
- NCT02201407
- Testing
- Peginterferon alfa-2a
- Where
- 6 sites in Serbia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Chronic Hepatitis B
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
- Trial name
- NCT06566248
- Testing
- TQA3810 tablets+NUC
- Where
- 6 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis C
Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine
The objectives are 1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine. 2.
- Trial name
- NCT00602784
- Testing
- IC41
- Volunteers
- 66 people
- Sponsor
- Valneva Austria GmbH
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
Hepatitis C, Chronic
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g.
- Trial name
- NCT01447446
- Testing
- Peg-IFN Alfa-2a, Peg-IFN Alfa-2b, Ribavirin
- Where
- 271 sites in Belgium, Egypt and 25 more
- Volunteers
- 4,442 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04059198
- Testing
- Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF)
- Where
- 2 sites in Hong Kong
- Volunteers
- 5 people
- Sponsor
- F-star Therapeutics, Inc.
Chronic Hepatitis B Infection
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment…
- Trial name
- NCT07342881
- Testing
- Pevifoscorvir Sodium (ALG-000184)
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Hepatitis C, Liver Disease
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination…
- Trial name
- NCT02094443
- Testing
- Alisporivir, Ribavirin
- Where
- 16 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01604291
- Where
- 21 sites in Israel
- Volunteers
- 991 people
- Sponsor
- Hoffmann-La Roche